Updated on 25 August 2026
Pre-Series A
CEO at Microviable Therapeutics SL
Gijón, Spain
About
Microviable Therapeutics is a biotech company at preclinical stage developing novel biological medicines for oncology and infectious diseases. Our drugs are oral capsules containing naturally existing bacteria. These biological medicines are rationally designed to increase the efficacy of immunotherapy in solid tumors, and to ablate MDR-pathogenic bacteria in infectious diseases.
Microviable has three assets under development. Our lead candidate, MVT-201 (IP granted 2026), has finalized preclinical development, is currently under CMC aiming to start clinical trials in 2027 for CRC.
Until now, Microviable has secure 6M € funding combining competitive grants and equity. We are currently looking to raise a 3M € pre-series A funding to support our first-in-human clinical trial in colorectal cancer, and to advance the preclinical development of the other two assets.
Organisation
Similar opportunities
Partnership
Seeking opportunities for collaboration on the production of ATMPs in Spain
- Manufacturing
Pilar Cerveró
Clinical Project Manager at ViroFend Therapeutics
Salamanca, Spain
Partnership
Patent-Pending Nanotechnology Platform for Immune Cell–Tumor Cell Engagement
- Development
Alejandro Baeza García
Profesor Titular Universidad at Grupo de Nanotecnologia Orgánica - UPM
Madrid, Spain
Investment
Patent-Pending Nanotechnological Platform to Redirect Immune Cells Against Cancer
- Startup
- Healthcare
- Nano- and Microtechnologies
- Biotech, Pharma and Cosmetics
Alejandro Baeza García
Profesor Titular Universidad at Grupo de Nanotecnologia Orgánica - UPM
Madrid, Spain